Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells

Blood

Volumn 113, Issue 4, 2009, Pages 856-865

  Rosati, Emanuela ^a   Sabatini, Rita ^a   Rampino, Giuliana ^a   Tabilio, Antonio ^b   Di Ianni, Mauro ^b   Fettucciari, Katia ^a   Bartoli, Andrea ^a   Coaccioli, Stefano ^a   Screpanti, Isabella ^c   Marconi, Pierfrancesco ^a,d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Department of Clinical and Experimental Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED 2 PROTEIN; JAGGED1; MEMBRANE PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER RESISTANCE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; EX VIVO STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR INTRINSIC ACTIVITY;

APOPTOSIS; B-LYMPHOCYTES; CALCIUM-BINDING PROTEINS; CELL SURVIVAL; DOWN-REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; NF-KAPPA B; RECEPTORS, NOTCH; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 59649083306     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-139725     Document Type: Article

References (50)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
2. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000;7:223-234.
3. Cuní S, Pe'rez-Aciego P, Pe'rez-Chaco'n G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18:1391-1400.
4. Zaninoni A, Imperiali FG, Pasquini C, Zanella A, Barcellini W. Cytokine modulation of nuclear factor- kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol. 2003;31:185-190.
5. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91:2387-2396.
6. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia Bcell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109:703-710.
7. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res. 2000;79:157-173.
8. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006; 107:2223-2233.
9. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770-776.
10. Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 1999;181:393-409.
11. Allman D, Punt JA, Izon DJ, Aster JC, Pear WS. An invitation to T and more: Notch signaling in lymphopoiesis. Cell. 2002;109(suppl):1-11.
12. Kopan R. Notch: a membrane-bound transcription factor. J Cell Sci. 2002;115:1095-1097.
13. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature. 1995;377:355-358.
14. Kato H, Taniguchi Y, Kurooka H, et al. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development. 1997; 124:4133-4141.
15. Davis RL, Turner DL. Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene. 2001;20:8342-8357.
16. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194:237-255.
17. Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF-kappaB and T-cell leukemia/ lymphoma in Notch3 transgenic mice. EMBO J. 2000;19:3337-3348.
18. Lee SY, Kumano K, Masuda S, et al. Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia. 2005;19:1841-1843.
19. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004;104:3697-3704.
20. Jundt F, Anagnostopoulos I, Fö rster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398-3403.
21. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103:3503-3510.
22. Hubmann R, Schwarzmeier JD, Shehata M, et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002;99:3742-3747.
23. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia. 2005;19:260-267.
24. Hajdu M, Sebestye'n A, Barna G, et al. Activity of the Notch-signalling pathway in circulating human chronic lymphocytic leukaemia cells. Scand J Immunol. 2007;65:271-275.
25. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
26. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 1977;40:855-864.
27. van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
28. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable- region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
29. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
30. Blaumueller CM, Artavanis-Tsakonas S. Comparative aspects of Notch signaling in lower and higher eukaryotes. Perspect Dev Neurobiol. 1997;4:325-343.
31. Wolfe MS. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem. 2001;44:2039-2060.
32. Josien H. Recent advances in the development of-secretase inhibitors. Curr Opin Drug Discov Dev. 2002;5:513-525.
33. Masdehors P, Merle-Be' ral H, Maloum K, Omura S, Magdele'nat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000;96:269-274.
34. Wu G, Lyapina S, Das I, et al. SEL-10 is an inhibitor of Notch signaling that targets Notch for ubiquitin- mediated protein degradation. Mol Cell Biol. 2001;21:7403-7415.
35. Jehn BM, Dittert I, Beyer S, von der Mark K, Bielke W. c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1. J Biol Chem. 2002;277:8033-8040.
36. Saxena MT, Schroeter EH, Mumm JS, Kopan R. Murine Notch homologs (N1-4) undergo presenilin- dependent proteolysis. J Biol Chem. 2001; 276:40268-40273.
37. Curry CL, Reed LL, Nickoloff BJ, Miele L, Foreman KE. Notch-independent regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human endothelial cells. Lab Invest. 2006;86:842-852.
38. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003;22:6598-6608.
39. Palaga T, Miele L, Golde TE, Osborne BA. TCRmediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J Immunol. 2003;171:3019-3024.
40. Deftos ML, He YW, Ojala EW, Bevan MJ. Correlating Notch signaling with thymocyte maturation. Immunity. 1998;9:777-786.
41. Nickoloff BJ, Hendrix MJ, Pollock PM, Trent JM, Miele L, Qin JZ. Notch and NOXA-related pathways in melanoma cells. J Invest Dermatol Symp Proc. 2005;10:95-104.
42. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005; 24:6333-6344.
43. Cuevas IC, Slocum AL, Jun P, et al. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res. 2005;65:5070-5075.
44. Hartmann T, Bieger SC, Bruhl B, et al. Distinct sites of intracellular production for Alzheimer's disease A-40/42 amyloid peptides. Nat Med. 1997;3:1016-1020.
45. Shin HM, Minter LM, Cho OH, et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J. 2006;25:129-138.
46. Oswald F, Liptay S, Adler G, Schmid RM. NFkappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol. 1998;18: 2077-2088.
47. Braeuer SJ, Büneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res. 2006;4:715-728.
48. Sade H, Krishna S, Sarin A. The anti-apoptotic effect of Notch-1 requires p561ck-dependent, Akt/ PKB-mediated signaling in T cells. J Biol Chem. 2004;279:2937-2944.
49. Liu WH, Hsiao HW, Tsou WI, Lai MZ. Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation. EMBO J. 2007; 26:1660-1669.
50. Liu WH, Hsiao HW, Tsou WI, Lai MZ. Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation. EMBO J. 2007; 26:1660-1669.